References
- Alfthan O, Holsti LR. Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol. 1969;3:183–187.
- Hedlund PO, Damber JE, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostate cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No.5. Scand J Urol Nephrol. 2008;42:220–9.
- Shah SIA, Abel PD, Duong T, et al. Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer? Scand J Urol. 2014;48:411–412.
- Turo R, Smolski M, Esler R, et al. Diethylstilboestrol for the treatment of prostate cancer: past, present and future. Scand J Urol. 2014;48:4–14.
- Tombal B, Borre M, Rathenborg P, et al. Long-term efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 2015;68:787–794.
- Golan R, Scovell JM, Ramasamy R, et al. Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male. 2015;18:201–4.
- Veldhuis JD, Takahashi PY, Keenan DM, et al. Age disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men. Am J Physiol Endocrinol Metab. 2010;299:E675–82.
- Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16:249–68.